Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$17.67M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
37.95%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
-$1.808M
Q2 2024
Cash
Q2 2024
P/E
-0.06158
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $12.23M $8.817M $4.973M $4.629M $114.5K $12.34K
YoY Change 38.71% 77.29% 7.44% 3942.86% 827.88%
% of Gross Profit
Research & Development $3.915M $1.787M $2.225M $936.8K $484.1K $209.9K
YoY Change 119.02% -19.65% 137.47% 93.51% 130.59%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $16.15M $10.60M $7.198M $5.566M $598.6K $222.3K
YoY Change 52.25% 47.33% 29.32% 829.79% 169.3%
Operating Profit -$16.15M -$10.60M -$7.198M
YoY Change 52.25% 47.33%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense -$9.170K $5.237K -$2.806M -$614.0K
YoY Change -275.1% -100.19% 357.01%
% of Operating Profit
Other Income/Expense, Net -$2.090M -$4.197M -$285.2K -$1.569M
YoY Change -50.21% 1371.67% -81.83%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$18.29M -$14.80M -$10.23M -$7.826M -$598.6K -$222.3K
YoY Change 23.56% 44.7% 30.7% 1207.36% 169.3%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.29M -$14.80M -$10.23M -$7.826M -$598.6K -$222.3K
YoY Change 23.58% 44.69% 30.7% 1207.36% 169.3%
Net Earnings / Revenue
Basic Earnings Per Share -$11.00 -$1.69 -$1.53
Diluted Earnings Per Share -$11.00 -$1.69 -$868.4K -$664.4K -$59.86K -$22.23K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $4.711M $1.902M $444.1K $1.124M $24.95K $9.320K
YoY Change 147.68% 328.27% -60.48% 4403.53% 167.7%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $969.8K $302.4K
YoY Change 220.66%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $5.680M $2.204M $444.1K $1.124M $24.95K $9.320K
YoY Change 157.69% 396.37% -60.48% 4403.53% 167.7%
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $204.8K $0.00
YoY Change -100.0%
Total Long-Term Assets $0.00 $0.00 $204.8K $0.00 $0.00 $0.00
YoY Change -100.0%
Total Assets $5.680M $2.204M $648.9K $1.124M $24.95K $9.320K
YoY Change
Accounts Payable $811.7K $722.0K $736.3K $346.1K $41.02K $0.00
YoY Change 12.43% -1.94% 112.73% 743.71%
Accrued Expenses $965.1K $1.019M $680.0K $633.7K $66.90K $4.150K
YoY Change -5.3% 49.86% 7.31% 847.23% 1512.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $173.5K $0.00 $611.6K $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.795M $2.096M $10.76M $5.752M $123.3K $6.600K
YoY Change -14.33% -80.52% 87.02% 4567.07% 1767.42%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K
YoY Change
Total Long-Term Liabilities $500.0K $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $2.295M $2.096M $10.76M $5.752M $123.3K $6.600K
YoY Change 9.54% -80.52% 87.02% 4567.07% 1767.42%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 1.663M 8.742M 6.666M
Diluted Shares Outstanding 1.663M 8.742M 6.666M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.0879 Million

About PaxMedica, Inc.

PaxMedica, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Tarrytown, New York and currently employs 6 full-time employees. The company went IPO on 2022-08-19. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Industry: Pharmaceutical Preparations Peers: Emmaus Life Sciences, Inc. Elicio Therapeutics, Inc. Real Brands, Inc. Cingulate Inc. JOHNSON & JOHNSON LANNETT CO INC Mystic Holdings Inc./NV Zynerba Pharmaceuticals, Inc.